Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin

J Int Med Res. Nov-Dec 2008;36(6):1273-8. doi: 10.1177/147323000803600614.


The aim of this study was to evaluate the efficacy of recombinant adenovirus p53 agent (rAd-p53) injection combined with cisplatin (CDDP) for the treatment of malignant pleural or peritoneal effusion. After puncture drainage, patients in the treatment group (n = 27) received intracavitary administration of rAd-p53 (2 x 10(12) virus particles) once a week for 4 weeks. At 48 h after each rAd-p53 injection, patients were given intracavitary administration of cisplatin 60 mg/m(2). This administration procedure continued once a week for 4 weeks. The control group (n = 21) received the same intracavitary therapy as the treatment group but without rAd-p53 therapy. Efficacy was evaluated by clinical observations, computed tomography, tumour markers, Karnofsky score and short-term follow-up. The total effective rates for the treatment group (63.0%) were significantly higher than for the control group (42.9%), suggesting that the treatment group benefited over the control group. In conclusion, rAd-p53 therapy is a safe and effective treatment for advanced malignant pleural or peritoneal effusion.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviruses, Human / genetics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Ascites / blood
  • Ascites / pathology
  • Ascites / therapy*
  • Ascitic Fluid / drug effects
  • Ascitic Fluid / pathology
  • Biomarkers, Tumor / blood
  • Cisplatin / therapeutic use*
  • Combined Modality Therapy
  • Female
  • Genes, p53
  • Genetic Therapy*
  • Humans
  • Male
  • Middle Aged
  • Pleural Effusion, Malignant / blood
  • Pleural Effusion, Malignant / pathology
  • Pleural Effusion, Malignant / therapy*
  • Recombinant Proteins / therapeutic use*
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / therapeutic use*


  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Recombinant Proteins
  • Tumor Suppressor Protein p53
  • Cisplatin